Claims for Patent: 10,835,578

Summary for Patent: 10,835,578

Title:	CNP prodrugs with large carrier moieties
Abstract:	The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.
Inventor(s):	Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
Assignee:	Ascendis Pharma Endocrinology Division AS
Application Number:	US16/067,057
Patent Claims:	1. A CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety -Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and -Z comprises a branched polymer having a molecular weight of at least 10 kDa attached to a ring moiety of -D, wherein cleavage of -L1- releases -D in its free form. 2. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -Z comprises a branched polymer having one, two, three, four, five or six branching points. 3. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 2, wherein each branching point is independently selected from the group consisting of -N<, -CH< and >C<. 4. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -Z has a molecular weight ranging from and including 10 kDa to 80 kDa. 5. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -Z further comprises a moiety 6. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -Z comprises a moiety of formula (a) wherein the dashed line indicates attachment to -L2- or to the remainder of -Z; BPa is a branching point selected from the group consisting of -N<, -CR< and >C<; -R is selected from the group consisting of -H and C1-6 alkyl; a is 0 if BPa is -N< or -CR< and a is 1 if BPa is >C<; -Sa-, -Sa′-, -Sa″- and -Sa′″- are independently of each other a chemical bond or are selected from the group consisting of C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more -R1, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R2)-, -S(O)2N(R2)-, -S(O)N(R2)-, -S(O)2-, -S(O)-, -N(R2)S(O)2N(R2a)-, -S-, -N(R2)-, -OC(OR2)(R2a)-, -N(R2)C(O)N(R2a)-, and -OC(O)N(R2)-; each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more -R1, which are the same or different; each -R1 is independently selected from the group consisting of halogen, -CN, oxo (═O), -COOR3, -OR3, -C(O)R3, -C(O)N(R3R3a), -S(O)2N(R3R3a), -S(O)N(R3R3a), -S(O)2R3, -S(O)R3, -N(R3)S(O)2N(R3aR3b), -SR3, -N(R3R3a), -NO2, -OC(O)R3, -N(R3)C(O)R3a, -N(R3)S(O)2R3a, -N(R3)S(O)R3a, -N(R3)C(O)OR3a, -N(R3)C(O)N(R3aR3b), -OC(O)N(R3R3a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; each -R2, -R2a, R3, -R3a and -R3b is independently selected from the group consisting of -H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and -Pa′,-Pa″ and -Pa ′″ are independently a polymeric moiety. 7. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -Z is of formula (f) wherein the dashed line indicates attachment to -L2-; BPf is a branching point selected from the group consisting of -N<, -CR< and >C<; -R is selected from the group consisting of -H and C1-6 alkyl; f is 0 if BPf is -N< or -CR< and f is 1 if BPf is >C<; -Sf-, -Sf′-, -Sf″- and -Sf′″- are independently either a chemical bond or are independently selected from the group consisting of C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more -R1, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)O-, -O-, -C(O)-, -C(O)N(R2)-, -S(O)2N(R2)-, -S(O)N(R2)-, -S(O)2-, -S(O)-, -N(R2)S(O)2N(R2a)-, -S-, -N(R2)-, -OC(OR2)(R2a)-,-N(R2)C(O)N(R2a)-, and -OC(O)N(R2)-; each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more -R1, which are the same or different; each R1 is independently selected from the group consisting of halogen, -CN, oxo (═O), -COOR3, -OR3, -C(O)R3, -C(O)N(R3R3a), -S(O)2N(R3R3a), -S(O)N(R3R3a), -S(O)2R3, -S(O)R3, -N(R3)S(O)2N(R3aR3b), -SR3, -N(R3R3a), -NO2, -OC(O)R3, -N(R3)C(O)R3a, -N(R3)S(O)2R3a, -N(R3)S(O)R3a, -N(R3)C(O)OR3a, -N(R3)C(O)N(R3aR3b), -OC(O)N(R3R3a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; each -R2, -R2a, R3, -R3a and -R3b is independently selected from the group consisting of -H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and -Za′, -Za″and -Za′″are independently wherein BPa is a branching point selected from the group consisting of -N<, -CRC<; -R is selected from the group consisting of -H and C1-6 alkyl; a is 0 if BPa is -N< or -CR< and a is 1 if BPa is >C<; -Sa- , -Sa′- , -Sa″- and -Sa′″- are independently of each other a chemical bond or are selected from the group consisting of C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more -R1, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T- , -C(O)O-, -O-, -C(O)-, -C(O)N(R2)-, -S(O)2N(R2)-, -S(O)N(R2)-, -S(O)2-, -S(O)-, -N(R2)S(O)2N(R2a)-, -S-, -N(R2)-, -OC(OR2)(R2a)-, -N(R2)C(O)N(R2a)-, and -OC(O)N(R2)-; each -T- is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10) cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 1 1-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl, and 8- to 30-membered heteropolycyclyl; wherein each -T- is independently optionally substituted with one or more -R1, which are the same or different; each -R1 is independently selected from the group consisting of halogen, -CN, oxo (═O), -COOR3, -OR3, -C(O)R 3, -C(O)N(R3R3a), -S(O)2N(R3R3a), -S(O)N(R3R3a), -S(O)2R3, -S(O)R3, -N(R3)S(O)2N(R3aR3b), - SR3, -N(R3R3a), -NO2, -OC(O)R3, -N(R3)C(O)R3a, -N(R3)S(O)2R3a, -N(R3)S(O)R3a, NR3)C(O)OR3a, -N(R3)C(O)N(R3aR3b), -O(O)N(R3R3a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; each -R2, -R2a, R3 , -R3a and -R3b is independently selected from the group consisting of -H, and C1-6 alkyl, wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and -Pa′, -Pa″ - Pa′″′ are independently a polymeric moiety. 8. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -D has the sequence of SEQ ID NO:24, SEQ ID NO:25 or SEQ ID NO:30. 9. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein is conjugated to the side chain of an amino acid residue of the ring moiety of -D or to the backbone of the ring moiety of -D. 10. A pharmaceutical composition comprising at least one CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1 and at least one excipient. 11. A method of treating, controlling, delaying or preventing in a mammalian patient in need of the treatment of one or more diseases which can be treated with CNP, comprising the step of administering to said patient in need thereof a therapeutically effective amount of the CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1 or a pharmaceutical composition comprising the CNP prodrug. 12. The method of claim 11, wherein the one or more diseases which can be treated with CNP is selected from the group consisting of achondroplasia, hypochondroplasia, short stature, dwarfism, osteochondrodysplasias, thanatophoric dysplasia, osteogenesis imperfecta, achondrogenesis, chondrodysplasia punctata, homozygous achondroplasia, camptomelic dysplasia, congenital lethal hypophosphatasia, perinatal lethal type of osteogenesis imperfecta, short-rib polydactyly syndromes, rhizomelic type of chondrodysplasia punctata, Jansen-type metaphyseal dysplasia, spondyloepiphyseal dysplasia congenita, atelosteogenesis, diastrophic dysplasia, congenital short femur, Langer-type mesomelic dysplasia, Nievergelt-type mesomelic dysplasia, Robinow syndrome, Reinhardt syndrome, acrodysostosis, peripheral dysostosis, Kniest dysplasia, fibrochondrogenesis, Roberts syndrome, acromesomelic dysplasia, micromelia, Morquio syndrome, Kniest syndrome, metatrophic dysplasia, spondyloepimetaphyseal dysplasia, neurofibromatosis, Legius syndrome, LEOPARD syndrome, Noonan syndrome, hereditary gingival fibromatosis, neurofibromatosis type 1, Legius syndrome, cardiofaciocutaneous syndrome, Costello syndrome, SHOX deficiency, idiopathic short stature, growth hormone deficiency, osteoarthritis, cleidocranial dysostosis, craniosynostosis, dactyly, brachydactyly, camptodactyly, polydactyly, syndactyly, dyssegmental dysplasia, enchondromatosis, fibrous dysplasia, hereditary multiple exostoses, hypophosphatemic rickets, Jaffe- Lichtenstein syndrome, Marfan syndrome, McCune-Albright syndrome, osteopetrosis and osteopoikilosis. 13. The method of claim 11, wherein the one or more diseases which can be treated with CNP is achondroplasia. 14. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -Z has a molecular weight of about 40 kDa. 15. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -Z is of formula (h) wherein the dashed line indicates attachment to -L2-; and each -Zc is a moiety wherein each c1 is an integer independently ranging from about 200 to 250. 16. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -D has the sequence of SEQ ID NO:24. 17. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -D has the sequence of SEQ ID NO:24 and -Ll- is conjugated to the amine functional group of the side chain of the lysine at position 26 of SEQ ID NO:24. 18. The method of claim 11, wherein the one or more disease is Muenke syndrome, Crouzon syndrome, Apert syndrome, Jackson-Weiss syndrome, Pfeiffer syndrome, or Crouzonodermoskeletal syndrome. 19. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein Z has a molecular weight ranging from 10 to 250 kDa. 20. The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein Z has a molecular weight ranging from 12 to 100 kDa.